Ayyoub et al. raise two long-standing questions in their comment addressing the publication by Himmel et al. ([1][1]): what is the best way to define T regulatory cells (Tregs) from different origins in humans; and which population of Tregs is optimal for cell therapy applications? A consistent
No takes yet. Share an insight, caveat, or question.
MacDonald et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: